# Mylan Pharmaceuticals Inc.

Canonical: https://abierto.us/vendors/mylan-pharmaceuticals-inc-ndn1myb8dkk5

- UEI: NDN1MYB8DKK5
- CAGE: 3KJG9
- Parent: Viatris Inc.
- Location: Morgantown, WV
- Awards in window: 11 (81 transactions), $0 obligated, January 9, 2024 to August 21, 2026

## Awarding agencies

- Department of Veterans Affairs: 9 awards, $0
- Defense Logistics Agency: 2 awards, $0

## Industries

- 325412 Pharmaceutical Preparation Manufacturing: $0

## Competition

- Full and Open Competition: 11 awards

## Solicitations won

- Budesonide/Formoterol INH (36E79726R0013), $436,529,696. https://abierto.us/opportunities/36e79726r0013
- Clonidine Patches (36E79725R0037), $0. https://abierto.us/opportunities/36e79725r0037
- SPE2D2-22-D-0145 Estradiol Patch 24 Contract (SPE2D221R0115), $9,549,893. https://abierto.us/opportunities/spe2d221r0115
- Rivastigmine 24HR Patches (SPE2D221R0113), $10,967,220. https://abierto.us/opportunities/spe2d221r0113

## Largest awards

- 36E79719D0020: $0, Nac Pharmaceuticals. Change in Cost Recovery Fee Submittal and Sales Reporting Procedures. https://www.usaspending.gov/award/CONT_IDV_36E79719D0020_3600/
- 36E79720D0022: $0, Nac Pharmaceuticals. Change Timeframe for the Submission of Quarterly Sales Reports and Cost Recovery Fee to 30 Calendar Days After End of Each Fiscal Quarter.. https://www.usaspending.gov/award/CONT_IDV_36E79720D0022_3600/
- 36E79720D0035: $0, Nac Pharmaceuticals. Modification for the Supplemental Changes to the CRF Payment Submittal and Sales Reporting Requirements.. https://www.usaspending.gov/award/CONT_IDV_36E79720D0035_3600/
- 36E79721D0037: $0, Nac Pharmaceuticals. This Modification Is Issued to Update the Terms of the CRF Payment Remittal and Submission of Quarterly Sales Reports.. https://www.usaspending.gov/award/CONT_IDV_36E79721D0037_3600/
- 36E79721D0042: $0, Nac Pharmaceuticals. This Modification Is Issued to Update the Terms of the CRF Payment Remittal and Submission of Quarterly Sales Reports.. https://www.usaspending.gov/award/CONT_IDV_36E79721D0042_3600/
- 36E79723D0015: $0, Nac Pharmaceuticals. Exercise Option Year 1 Effective March 4, 2024 Through March 3, 2025 for Clozapine Tablets with Mylan Pharmaceuticals, INC. Prices Remain Unchanged.. https://www.usaspending.gov/award/CONT_IDV_36E79723D0015_3600/
- 36E79725D0054: $0, Nac Pharmaceuticals. 3 Line Items for Clonidine Patches. Awarded for a Base Year of 11/30/2025 to 11/29/2026.. https://www.usaspending.gov/award/CONT_IDV_36E79725D0054_3600/
- 36E79726D0033: $0, Nac Pharmaceuticals. 2 Line Items for Budesonide/Formoterol Oral Inhalers. Awarded for a Base Year of 8/7/2026 to 8/6/2027 Plus 4 ONE-YEAR Periods.. https://www.usaspending.gov/award/CONT_IDV_36E79726D0033_3600/
- 36F79723D0025: $0, Nac Federal Supply Schedule. 65 I B, Sin 42-2B - Voluntary Temporary Price Reduction (Tpr) - for All FSS Users. https://www.usaspending.gov/award/CONT_IDV_36F79723D0025_3600/
- SPE2D222D0145: $0, DLA Troop Support. 4610093699!manufacture/Distributor BR-PH. https://www.usaspending.gov/award/CONT_IDV_SPE2D222D0145_9700/
- SPE2D222D0147: $0, DLA Troop Support. 4610094214!manufacture/Distributor Br-Philadelphia. https://www.usaspending.gov/award/CONT_IDV_SPE2D222D0147_9700/

---
Source: USAspending.gov award data, keyed by UEI. Obligations in the window only. Cite https://abierto.us/vendors/mylan-pharmaceuticals-inc-ndn1myb8dkk5.